BACKGROUND AND OBJECTIVES: Widely used in the treatment of psoriasis, biologics have been tested in numerous clinical trials. However, drug efficacies and adverse events (AEs) may differ in 'real-world' patients as they do not undergo as rigorous selection and monitoring. Our objective was to examine drug survival, efficacy, and AEs (quality, time of onset) in 'real-world' psoriasis patients treated with etanercept, adalimumab, and ustekinumab. PATIENTS AND METHODS: Retrospective data analysis (Jan 1, 2004 to Jun 30, 2015) of patients treated at a psoriasis clinic in an Austrian hospital. All patients who had received at least one dose of etanercept, adalimumab, or ustekinumab were included in the analysis. We analyzed: demographics, drug survival, Psoriasis Area and Severity Index (PASI), as well as quality and time of onset of AEs. RESULTS: In 209 treatment series, the estimated median drug survival varied among the various treatments: 21 months (SE: 6.9) for etanercept, 61 months (SE: 9.4) for adalimumab, and 65 months (SE 1.4) for ustekinumab. Male gender and pretreatment with a biologic were positive predictors of longer drug survival in adalimumab. We found no significant difference in drug efficacy as determined by PASI. CONCLUSIONS: Most AEs occur during the first year of treatment. Adalimumab and ustekinumab are marked by longer drug survival compared to etanercept.
BACKGROUND AND OBJECTIVES: Widely used in the treatment of psoriasis, biologics have been tested in numerous clinical trials. However, drug efficacies and adverse events (AEs) may differ in 'real-world' patients as they do not undergo as rigorous selection and monitoring. Our objective was to examine drug survival, efficacy, and AEs (quality, time of onset) in 'real-world' psoriasispatients treated with etanercept, adalimumab, and ustekinumab. PATIENTS AND METHODS: Retrospective data analysis (Jan 1, 2004 to Jun 30, 2015) of patients treated at a psoriasis clinic in an Austrian hospital. All patients who had received at least one dose of etanercept, adalimumab, or ustekinumab were included in the analysis. We analyzed: demographics, drug survival, Psoriasis Area and Severity Index (PASI), as well as quality and time of onset of AEs. RESULTS: In 209 treatment series, the estimated median drug survival varied among the various treatments: 21 months (SE: 6.9) for etanercept, 61 months (SE: 9.4) for adalimumab, and 65 months (SE 1.4) for ustekinumab. Male gender and pretreatment with a biologic were positive predictors of longer drug survival in adalimumab. We found no significant difference in drug efficacy as determined by PASI. CONCLUSIONS: Most AEs occur during the first year of treatment. Adalimumab and ustekinumab are marked by longer drug survival compared to etanercept.
Authors: Marloes E Van Muijen; Sarah E Thomas; Hans M M Groenewoud; Marisol E Otero; Paul M Ossenkoppele; Marcellus D Njoo; Sharon R P Dodemont; Else N Kop; Maartje A M Berends; Marjolein I A Koetsier; Johannes M Mommers; John E M Körver; Ron A Tupker; Marjolein S De Bruin-Weller; Lizelotte J M T Weppner-Parren; Bas Peters; Marloes M Kleinpenning; Astrid L A Kuijpers; W Peter Arnold; Paula P M Van Lümig; Juul M P A Van den Reek; Elke M G J De Jong Journal: Acta Derm Venereol Date: 2022-05-16 Impact factor: 3.875
Authors: Carlos Pelayo Hernández-Fernández; Gregorio Carretero; Raquel Rivera; Carlos Ferrándiz; Esteban Daudén; Pablo de Cueva; Isabel Belinchón; Francisco Javier Gómez-García; Enrique Herrera-Acosta; Diana P Ruiz-Genao; Marta Ferrán; Mercé Alsina; Ofelia Baniandrés-Rodríguez; José Luis Sánchez-Carazo; Rafael Botella-Estrada; Antonio Sahuquillo-Torralba; Lourdes Rodríguez; Jaime Vilar-Alejo; Carmen García-Donoso; José M Carrascosa; Mar Llamas-Velasco; Enrique Herrera-Ceballos; Jose Luis López-Estebaranz; Conrad Pujol-Marco; Miguel Angel Descalzo; Ignacio Garcia-Doval Journal: Acta Derm Venereol Date: 2021-01-04 Impact factor: 3.875